Growth capital for the life sciences

Which funding options are available to start-ups as well as to small- and medium-sized enterprises? The search for investors is often not easy for young life sciences companies. A deep insight into the current challenges and solutions will be provided by the analytica Finance Day, organized by Going Public Media, which will be taken place again at analytica Biotech Forum.

Financing opportunities for the life sciences

The Finance Day has been devoting itself to the start-up, growth and capital market financing of life science companies for 14 years.

At the Finance Day, company representatives will be reporting on the options they have used on their growth path. They will be providing practical insights into the issues concerned, thus giving visitors ideas for their own corporate financing.

Program Finance Days 2020

14:30 Uhr – Opening and Introduction „Finance Days“
Moderation: Benjamin Heimlich, Chefredakteur VentureCapital Magazin (Englisch)

14:35 – 15:00 – Keynote: Fundraising Lessons Learned
Marc Filerman, Chief Executive Officer, German Life Science Accelerator (Englisch)

10:05 – 10:30 Uhr – Impuls „Vom Start-Up zum Global Player“ (German)
Dr. Sierk Poetting, Chief Financial Officer und Chief Operating Officer, BioNtech und Michael Motschmann, Executive Board, MIG Verwaltungs AG im Gespräch mit Mathias Renz, Relationship Manager GoingPublic Media

10:30 – 11:30 Uhr – Panel 1: Venture Capital & Co.: Aktuelle Finanzierungstrends in der Biotechnologie (German)
Moderation: Holger Garbs, Redakteur, Plattform Life Sciences

Andreas Huber, Senior Investment Manager, Bayern Kapital
Dr. Aristoteles Nastos, Head of Venture Capital Life Science & Cleantech, NRW BANK & CEO Gründerfonds Ruhr
Dr. Bernhard Noreisch, Rechtsanwalt und Partner, Lutz Abel PartG mbB
Dr. Sebastian Pünzeler, Investment Manager (Life Sciences), coparion
Marco Winzer, Partner, High-Tech Gründerfonds

12:00 –13:00 Uhr – Panel 2: Pharma and Biotech: New finance models for former Life Science Companies
Moderation: Dr. Hubert Birner, Managing Partner TVM Life Science Management

Michael Salzmann, Chief Executive Officer, AL-S Pharma
Enno Spillner, Chief Financial Officer, Evotec AG

14:30 – 15:30 Uhr – Panel 3: Stock exchange and IPO: „IPO – a piece of cake?”
Moderation: Thomas Strassner, Partner, Dentons Europe LLP

Sebastian Grabert, Director – Germany Representative, EURONEXT
Adam Kostyál, Senior Vice President, Nasdaq Stockholm
Dieter Lingelbach, Managing Director, SIRION Biotech
Frans-Matthis Pleie, Director, Bryan-Garnier
Richard Stoffelen, Chief Financial Officer, Centogene

16:00 – 17:00 Uhr – Panel 4: China – Opportunities and challenges for Life Sciences Companies

Dr. Albrecht Läufer, Chief Executive Officer, BluCon Biotech
Dr. Kai Lamottke, Managing Director, Bicoll
Dr. Ernst Ludes, Managing Director, CV Capital
Rafael Ratzel, Executive Director, Head of International Business Department, Tsinghua Capital Holdings
Dr. Jan zur Hausen, Partner, EC Healthcare Fund

Ab ca. 17:00 Uhr – Networking Reception Finance Days – Drinks & Snacks

10:05 – 10:35 Uhr – Keynote: Neue Methoden in der Humangenetik – der Weg zur Präzisionsmedizin (German)
Dr. Dr. Saskia Biskup, Chief Executive Officer, CeGaT und Praxis für Humangenetik, Tübingen

10:35 –11:35 Uhr Panel 1: „Von der Diagnostik zur zielgerichteten Therapie – Was ist in der individualisierten Medizin bereits möglich?“ (German)
Moderation: Dr. Pablo Serrano, Geschäftsfeldleiter Innovation & Forschung/Biotechnologie, Bundesverband der Pharmazeutischen Industrie e.V.

Dr. Christian Meisel, Chief Medical Officer, Molecular Health
Nicolas Schauer, Co- Chief Executive Officer and Chief Security Officer, Biocrates
Steffen Schuster, Chief Executive Officer, ITM Isotopen Technologien

11:35 – 12:05 Uhr – Vortrag 1: KI in der Leukämiediagnostik: Wie sieht die Diagnostik der Zukunft aus? (German)
Prof. Dr. Dr. Torsten Haferlach, , Chief Executive Officer, MLL Münchner Leukämielabor

14:30 – 15:00 Uhr – analytica Start-up Award Ceremony / Resüme